Results 11 to 20 of about 912 (125)

SITAGLIPTIN; SITAGLIPTIN AS ADD ON THERAPY TO PATIENTS ON INSULIN.

The Professional Medical Journal, 2017
The objective of this stidy is to compare the mean reduction of HbA1c in patientstaking sitagliptin insulin combination with insulin alone in patients of type II Diabetes mellitus.Study Design: Randomized control trial (RCT). Setting: Medicine Department, Allied Hospital,Faisalabad. Period: August 2013 to February 2014.
Zaheer Ahmed, Hassan Fareed, Muhammad Usman Musharraf   +2 more
openaire   +2 more sources

Sitagliptin Stimulates Endothelial Progenitor Cells to Induce Endothelialization in Aneurysm Necks Through the SDF-1/CXCR4/NRF2 Signaling Pathway

Frontiers in Endocrinology, 2019
Aneurysm (AN) embolization is an important treatment for cerebral aneurysms. The endothelialization of the aneurysm neck is crucial for preventing aneurysm recurrence.
Guo Yu, Guo Yu, Peixi Liu, Peixi Liu, Yuan Shi, Yuan Shi, Sichen Li, Sichen Li, Yingjun Liu, Yingjun Liu, Wei Zhu, Wei Zhu   +11 more
doaj   +1 more source

An Effective Delivery System of Sitagliptin Using Optimized Mucoadhesive Nanoparticles

Applied Sciences, 2018
Sitagliptin (MK-0431), is a potent oral hypoglycemic drug that is used for treating type 2 diabetes mellitus. However, the short half-life of sitagliptin requires patients to take a high dose of 50 mg twice per day, and the fraction of sitagliptin ...
Afzal Haq Asif, Sree Harsha, Niranjan Hodalur Puttaswamy, Bandar E. Al-Dhubiab   +3 more
doaj   +1 more source

PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness

BMJ Open Diabetes Research & Care, 2020
Introduction Sitagliptin is a dipeptidyl peptidase 4 inhibitor for the treatment of type 2 diabetes (T2D). Limited real-world data on its effectiveness and safety are available from an Italian population.Research design and methods We evaluated long-term
Antonio Carlo Bossi, Valentina De Mori, Carlotta Galeone, Davide Pietro Bertola, Margherita Gaiti, Annalisa Balini, Denise Berzi, Franco Forloni, Giancarla Meregalli, Federica Turati   +9 more
doaj   +1 more source

Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study

Scientific Reports, 2023
Sitagliptin has been suggested as a treatment option for older adults with type 2 diabetes (T2D). However, no randomized controlled trial has been performed to evaluate the efficacy and safety of sitagliptin treatment in older Japanese patients with T2D.
Mototsugu Nagao, Jun Sasaki, Hitoshi Sugihara, Kyoko Tanimura-Inagaki, Taro Harada, Ichiro Sakuma, Shinichi Oikawa, STREAM Study Investigators   +7 more
doaj   +1 more source

Beneficial effects of sitagliptin ,metformin and their combination on myocardial ischemic and vascular changes in type-two diabetic rats [PDF]

Zagazig University Medical Journal, 2021
Background: Myocardial infarction is a critical complication frequently occurs with type2diabetes mellitus. Sitagliptin is antidiabetic drug inhibits DPP-4,which augments endogenous levels of GLP-1.Metformin is an FDA-approved antidiabetic drug, which ...
Kamal ElKashishy, Soad Kabil, Monira Khattab, Nabila Fahmy, Yassmen EL-sayed   +4 more
doaj   +1 more source

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

Cardiovascular Diabetology, 2013
Objective To compare the incidence of cardiovascular events and mortality in patients with type 2 diabetes mellitus treated with sitagliptin or non-sitagliptin comparators.
Engel Samuel S, Golm Gregory T, Shapiro Deborah, Davies Michael J, Kaufman Keith D, Goldstein Barry J   +5 more
doaj   +1 more source

Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. [PDF]

PLoS ONE, 2015
BACKGROUND:The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients after acute myocardial infarction (AMI) has so far remained uncertain.
Szu-Heng Wang, Dong-Yi Chen, Yu-Sheng Lin, Chun-Tai Mao, Ming-Lung Tsai, Ming-Jer Hsieh, Chung-Chuan Chou, Ming-Shien Wen, Chun-Chieh Wang, I-Chang Hsieh, Kuo-Chun Hung, Tien-Hsing Chen   +11 more
doaj   +1 more source

Significance of Vascular Dipeptidyl Peptidase-4 Inhibition on Vascular Protection in Zucker Diabetic Fatty Rats

Journal of Pharmacological Sciences, 2014
.: To clarify the role of dipeptidyl peptidase-4 (DPP-4) inhibition in vascular tissues, we compared the effects of the poorly tissue-penetrative DPP-4 inhibitor sitagliptin to the highly tissue-penetrative DPP-4 inhibitor linagliptin in Zucker diabetic ...
Shinji Takai, Hiroshi Sakonjo, Denan Jin
doaj   +1 more source

Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. [PDF]

PLoS ONE, 2012
BackgroundRecently, it has been suggested that enhancement of incretin effect improves cardiac function. We investigated the effect of a DPP-IV inhibitor, des-fluoro-sitagliptin, in reducing occurrence of restenosis in carotid artery in response to ...
Soo Lim, Sung Hee Choi, Hayley Shin, Bong Jun Cho, Ho Seon Park, Byung Yong Ahn, Seon Mee Kang, Ji Won Yoon, Hak Chul Jang, Young-Bum Kim, Kyong Soo Park   +10 more
doaj   +1 more source